Vetoquinol (VETO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vetoquinol (VETO) has a cash flow conversion efficiency ratio of 0.026x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€14.72 Million ≈ $17.21 Million USD) by net assets (€567.53 Million ≈ $663.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Vetoquinol stock valuation for the company's overall valuation and market capitalisation.
Vetoquinol - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Vetoquinol's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Vetoquinol stock price today for real-time trading data and today's change.
Vetoquinol Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vetoquinol ranked by their cash flow conversion efficiency. Review VETO free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
0.004x |
|
Supalai Public Company Limited
BK:SPALI-R
|
0.012x |
|
Deluxe Corporation
NYSE:DLX
|
0.076x |
|
Ye Chiu Metal Recycling China Ltd
SHG:601388
|
-0.026x |
|
FERRETTI S.P.A. O.N.
F:F3T1
|
N/A |
|
WUS Printed Circuit Co Ltd
TW:2316
|
-0.028x |
|
Grupo Herdez S.A.B. de C.V
MX:HERDEZ
|
-0.014x |
|
Shunfa Hengye Corp
SHE:000631
|
0.000x |
Annual Cash Flow Conversion Efficiency for Vetoquinol (2004–2024)
The table below shows the annual cash flow conversion efficiency of Vetoquinol from 2004 to 2024. Also see VETO asset base for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €575.93 Million ≈ $673.33 Million |
€85.83 Million ≈ $100.34 Million |
0.149x | -12.13% |
| 2023-12-31 | €527.11 Million ≈ $616.25 Million |
€89.39 Million ≈ $104.51 Million |
0.170x | +30.77% |
| 2022-12-31 | €484.66 Million ≈ $566.62 Million |
€62.85 Million ≈ $73.48 Million |
0.130x | -36.20% |
| 2021-12-31 | €441.35 Million ≈ $515.99 Million |
€89.72 Million ≈ $104.89 Million |
0.203x | -18.05% |
| 2020-12-31 | €371.83 Million ≈ $434.71 Million |
€92.23 Million ≈ $107.83 Million |
0.248x | +84.03% |
| 2019-12-31 | €385.98 Million ≈ $451.25 Million |
€52.02 Million ≈ $60.82 Million |
0.135x | +29.18% |
| 2018-12-31 | €363.08 Million ≈ $424.48 Million |
€37.88 Million ≈ $44.29 Million |
0.104x | -15.03% |
| 2017-12-31 | €335.73 Million ≈ $392.50 Million |
€41.23 Million ≈ $48.20 Million |
0.123x | -10.05% |
| 2016-12-31 | €316.48 Million ≈ $369.99 Million |
€43.20 Million ≈ $50.51 Million |
0.137x | +1.61% |
| 2015-12-31 | €289.49 Million ≈ $338.45 Million |
€38.90 Million ≈ $45.47 Million |
0.134x | -12.68% |
| 2014-12-31 | €268.40 Million ≈ $313.78 Million |
€41.30 Million ≈ $48.28 Million |
0.154x | +29.18% |
| 2013-12-31 | €235.96 Million ≈ $275.86 Million |
€28.11 Million ≈ $32.86 Million |
0.119x | -20.61% |
| 2012-12-31 | €228.01 Million ≈ $266.57 Million |
€34.21 Million ≈ $39.99 Million |
0.150x | +5.70% |
| 2011-12-31 | €211.29 Million ≈ $247.02 Million |
€29.99 Million ≈ $35.06 Million |
0.142x | -23.87% |
| 2010-12-31 | €184.27 Million ≈ $215.43 Million |
€34.36 Million ≈ $40.17 Million |
0.186x | -27.85% |
| 2009-12-31 | €154.95 Million ≈ $181.15 Million |
€40.05 Million ≈ $46.82 Million |
0.258x | +61.72% |
| 2008-12-31 | €137.05 Million ≈ $160.23 Million |
€21.90 Million ≈ $25.61 Million |
0.160x | -45.09% |
| 2007-12-31 | €127.87 Million ≈ $149.49 Million |
€37.22 Million ≈ $43.51 Million |
0.291x | +38.50% |
| 2006-12-31 | €111.15 Million ≈ $129.94 Million |
€23.36 Million ≈ $27.31 Million |
0.210x | -39.22% |
| 2005-12-31 | €86.82 Million ≈ $101.50 Million |
€30.01 Million ≈ $35.09 Million |
0.346x | +19.09% |
| 2004-12-31 | €71.38 Million ≈ $83.45 Million |
€20.72 Million ≈ $24.23 Million |
0.290x | -- |
About Vetoquinol
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal … Read more